Conference Coverage
Conference Coverage
Treat-to-target strategy with tapering proves effective in PsA and axSpA
A trial showed for the first time that disease activity–guided treat-to-target tapering strategies in both psoriatic arthritis and axial...
Conference Coverage
Bimekizumab calms psoriatic arthritis in phase 3 ‘BE’ trials
The dual interleukin-17 inhibitor was effective both in patients for whom TNF inhibitors failed and those who had never received a biologic...
Conference Coverage
‘Shielding’ status provides best indicator of COVID-19 mortality in U.K. arthritis population
Shielding status was the highest ranked of all the risk factors identified for early mortality from COVID-19.
Conference Coverage
Serious infection hospitalizations have declined in patients with PsA
Sepsis, urinary tract infections, and skin and soft-tissue infections declined among patients with PsA from 2012 to 2017 in the National Inpatient...
Conference Coverage
Psoriatic arthritis health care costs continue to rise over time
In a database claims review, the average person with PsA had higher inpatient, outpatient, and pharmacy costs, compared with those with only...
Conference Coverage
Physicians question the future of TNF inhibitors for psoriasis, PsA
Two dermatologists and two rheumatologists debate the merits of using IL-17 and IL-23 inhibitors ahead of TNF inhibitors for the treatment of...
Conference Coverage
Experts highlight recent breakthroughs in psoriatic arthritis
Signal of possible gender disparity in PsA response to biologics sparks questions.
Conference Coverage
To improve psoriatic arthritis outcomes, address common comorbidities
Depression and obesity are associated with poor treatment response in PsA.
Conference Coverage
Anybody for a nanobody? Novel psoriasis therapy impresses in phase 2b
Sonelokinab, which inhibits interleukin-17A/F, provided exceptionally rapid clinical improvement.
Conference Coverage
The case for anti–IL-17 agents as first-line biologics in psoriatic arthritis
“The guidelines don’t give full credit to the anti–IL-17 agents.”